Ornopia, Linda B.

HRN: 04-18-32  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/29/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/29/2022
11/04/2022
IV
500 Mg
Q8H
Intestinal Amoebiasis
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Intra-abdominal    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: